Imatinib dose optimisation following the disease progression in a patient with metastatic GIST
Here we report a case of a man affected by metastatic GIST since march 2007. His oncologic history began in 2006 when he was submitted to ileal resection and diagnosis of abdominal GIST was made. He was free of disease at radiologic controls until march 2007, when peritoneal nodules were shown. He s...
Main Authors: | Mariangela Parodi, Monica Boitano, Luciano Canobbio |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd
2015-10-01
|
Series: | Clinical Management Issues |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1123 |
Similar Items
-
Crossing-over to imatinib 800 mg in a patient with GIST, after progression with standard
dosage: a case report
by: Giuseppe Naso, et al.
Published: (2015-10-01) -
Imatinib as adjuvant therapy for high risk GIST: a case report
by: Patrizia Lista, et al.
Published: (2015-10-01) -
The management of metastatic GIST: current standard and investigational therapeutics
by: Ciara M. Kelly, et al.
Published: (2021-01-01) -
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
by: Seidel Christoph, et al.
Published: (2012-05-01) -
Appropriate durations of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumor (GIST) the better choice, for the year 2010
by: Lucia Tozzi
Published: (2015-10-01)